As per the founders, their lab-based
prototype of the novel, rapid, point-
of-care, low-cost, instrument-free
TB diagnostic kit is ready. They
are now gearing up for approvals
from the Central Drug Standards
Organization (CDSCO). Prior to
that, they would be preparing for
large-scale validation by third party
auditors. The Annweshan SciTech
team is confident that if all the
things including their financial
support expectations fall in place,
the patent-protected product could
be launched in India within 6-8
months from now.
“The product will be comfortably
priced for common people as well as
private sectors,” says Manikankana
while pointing out that if their
technology is accepted in the
Revised National Tuberculosis
Control Program (RNTCP), then
needy people will have access to it
free-of-cost.
“Our product can contribute
majorly to the worldwide
tuberculosis eradication program,
as early stage detection of the
disease is critical,” Manikankana
signs off on a confident note. And
in tune with the Indian spirit of
entrepreneurship, highly optimistic
one must say!
BIOVOICENEWS.COM
41